Associated Papers
PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.
Papanikolaou G et al.
Clinical Pharmacology and Therapeutics, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Eadon MT et al.
Clinical Pharmacology and Therapeutics, 2025
40974042 (PubMed )
Supplement: CPT-118-1430-s002.zip › NAT2_allele_definition_table.xlsx › Alleles
Pharmacogenomics in Orofacial Clefts Care: Insights from Whole-Genome Sequencing of Case-Parents Trios.
Poku-Adusei E et al.
Journal of Personalized Medicine, 2025
41149818 (PubMed )
Supplement: jpm-15-00456-s001.zip › jpm-3794577-supplementary.pdf
Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB et al.
Memorias Do Instituto Oswaldo Cruz, 2022
Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa.
Podgorná E et al.
Bmc Evolutionary Biology, 2015
26620671 (PubMed )
Supplement: 12862_2015_543_MOESM4_ESM.xlsx › Table_S1
Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure.
Teixeira RL et al.
Mutation Research, 2010
N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.
Hein DW
Expert Opinion on Drug Metabolism & Toxicology, 2009
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.
Matimba A et al.
Human Genomics, 2009
Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene.
Patin E et al.
Human Mutation, 2006
Select a paper to view details